Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.01), Zacks reports. Rapid Micro Biosystems had a negative return on equity of 177.04% and a negative net margin of 145.56%. The company had revenue of $9.53 million during the quarter, compared to analysts’ expectations of $9.85 million.
Rapid Micro Biosystems Stock Performance
Shares of Rapid Micro Biosystems stock opened at $0.74 on Tuesday. The company has a current ratio of 2.55, a quick ratio of 1.51 and a debt-to-equity ratio of 1.08. The stock’s fifty day moving average price is $0.91 and its 200-day moving average price is $2.06. The firm has a market cap of $37.12 million, a P/E ratio of -0.66 and a beta of 1.52. Rapid Micro Biosystems has a 12 month low of $0.58 and a 12 month high of $4.94.
Analysts Set New Price Targets
Several equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, October 15th. Lake Street Capital downgraded shares of Rapid Micro Biosystems from a “buy” rating to a “hold” rating and set a $0.75 target price on the stock. in a research note on Monday. JPMorgan Chase & Co. set a $0.75 target price on shares of Rapid Micro Biosystems in a research report on Tuesday. Finally, Roth Capital downgraded shares of Rapid Micro Biosystems from a “buy” rating to a “neutral” rating and decreased their price target for the company from $3.00 to $0.75 in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $1.81.
Check Out Our Latest Stock Report on RPID
Trending Headlines about Rapid Micro Biosystems
These are some of the RPID headlines that stood out recently:
- Positive Sentiment: Merck KGaA agreed to acquire Rapid Micro Biosystems for $0.75 per share in cash, with the transaction expected to close in December 2026. The offer is slightly above the cited $0.74 share price and gives investors a defined cash-out value; the limited premium also caps potential upside if the deal proceeds. Article: Rapid Micro Reports Marginally Lower Q3 Loss; Acquisition By Merck To Close In Dec ’26
- Neutral Sentiment: Merck said the acquisition would add Rapid Micro’s automated microbial testing platform to its pharmaceutical quality-control workflow offerings. Shareholder law firms have also announced investigations into whether the $0.75 offer is fair and how the deal was negotiated, adding uncertainty but not changing the announced terms. Article: Merck acquisition announcement Article: Shareholder investigation
- Negative Sentiment: Third-quarter results missed the cited analyst estimates: Rapid Micro reported a $0.22-per-share loss versus $0.21 expected and $9.53 million in revenue versus $9.85 million expected. The company also filed a notification of late filing. Article: Third-quarter 2026 results Article: Delayed quarterly filing
About Rapid Micro Biosystems
Rapid Micro Biosystems develops automated microbial detection systems for pharmaceutical, biotechnology and other life sciences manufacturers. Its products are designed to support quality-control testing by identifying and measuring microbial growth in manufacturing environments and products. The company’s Growth Direct platform combines laboratory instruments, consumables and software to automate microbial testing. Its applications include sterility testing, bioburden testing and environmental monitoring, helping manufacturers assess contamination during production.
Read More
- Five stocks we like better than Rapid Micro Biosystems
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
